Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1) → Larazotide

HRID 2172176노트

반응식

HRID 2172176 반응식
[CH3:1][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:42])[CH3:41])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:12])[CH3:11])=[O:7])[CH3:3].CC(O)=O>O>[CH3:3][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:41])[CH3:42])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:11])[CH3:12])=[O:7])[CH3:1]

참가 물질

3

반응물 1

HCID 44146842Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1)

생성물 1

HCID 9810532Larazotide

시약·촉매·용매 1

HCID 962Water용매

실험 절차

Solubilities of Larazotide acetate and the corresponding chloride salt in water were tested at 20° C. after 14 hours of vigorous stirring in the presence of residual solid. Concentrations of peptide are measured by standardized HPLC. The chloride salt is more soluble than the acetate salt.

출처 및 근거

ORD 기록
ord-1796805bfe664afeab2f1b5ea3d417a8
출처 데이터셋
uspto-grants-2015_06
특허 번호
US09051349B2

반응 노트

불러오는 중…